| Bethge, Wolfgang A |
| Recruiting | 3 | 210 | Europe | MC0518, BAT | medac GmbH | Steroid-refractory Acute Graft-versus-host Disease | 08/27 | 08/30 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
GRAPPA, NCT05153226: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG |
|
|
| Active, not recruiting | 3 | 640 | Europe | Cyclophosphamide, all brands, ATG, ATG Grafalon | DKMS gemeinnützige GmbH | Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS, MDS/MPN, CMML | 06/25 | 12/26 | | |
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy |
|
|
| Recruiting | 3 | 482 | Europe | Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD) | Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH | Multiple Myeloma | 03/28 | 03/33 | | |
| Completed | 2/3 | 98 | Europe | Peripheral blood stem cells, PBSC | DKMS gemeinnützige GmbH | AML, ALL, MDS | 04/24 | 04/24 | | |
NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia |
|
|
| Recruiting | 2 | 440 | Europe, RoW | Allogeneic Stem Cell Transplantation | Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG) | Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes | 11/22 | 11/24 | | |
| Recruiting | 2 | 27 | Europe | Decitabine, Dacogen, Venetoclax, Venclyxto, Venclexta | University Hospital Tuebingen | AML, MDS | 12/24 | 03/25 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 1/2 | 48 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells | Miltenyi Biomedicine GmbH | Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 29 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells | Miltenyi Biomedicine GmbH, Miltenyi Biomedicine GmbH | SLE - Systemic Lupus Erythematosus | 08/25 | 08/27 | | |
| Recruiting | 1/2 | 60 | Europe | CD45RA depleted donor lymphocyte infusion (DLI) | University Hospital Tuebingen, University Hospital Tuebingen | Hematologic Malignancy | 01/28 | 12/28 | | |
| Eigentler, Thomas |
| Completed | 2 | 45 | Europe | Dupilumab 300Mg Solution for Injection, Dupixent, Placebo | University of Cologne, Sanofi Aventis | Localized Scleroderma | 11/23 | 11/23 | | |
| Recruiting | 2 | 40 | Europe | L19IL2 +L19TNF, bifikafusp alfa + onfekafusp alfa | Philogen S.p.A., Philogen S.p.A. | Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell | 09/24 | 09/24 | | |
| Completed | 1/2 | 29 | Europe, US | ANV419, Pembrolizumab, Ipilimumab | Anaveon AG, Anaveon AG | Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma | 08/24 | 08/24 | | |
NCT03291002: Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC |
|
|
| Active, not recruiting | 1 | 98 | Europe, RoW | CV8102, CV8102 + anti-PD-1 therapy | CureVac AG, Syneos Health, Cromos Pharma LLC | Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic | 10/22 | 02/23 | | |
| Recruiting | 1 | 275 | Europe, Canada, US | PF-08046049 | Seagen Inc. | Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma | 11/26 | 11/27 | | |
NCT03683550: Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma |
|
|
| Active, not recruiting | N/A | 836 | Europe | SLNE with preoperative hybrid SPECT/CT, Standard SLNE | University Hospital, Essen | Melanoma | 06/25 | 06/25 | | |
| Noor, Seema |
| No trials found |
